Stockscreener 앱 받기
1.82
1.62%
-0.03
전일 마감가:
$1.85
열려 있는:
$1.9
하루 거래량:
6,102
Relative Volume:
0.23
시가총액:
$32.82M
수익:
-
순이익/손실:
$-21.91M
주가수익비율:
-9.9075
EPS:
-0.1837
순현금흐름:
-
1주 성능:
-12.92%
1개월 성능:
-19.47%
6개월 성능:
-34.53%
1년 성능:
+69.30%
1일 변동 폭
$1.80
$1.90
1주일 범위
$1.80
$2.11
52주 변동 폭
$0.9501
$12.68
Incannex Healthcare Inc Stock (IXHL) Company Profile
명칭
Incannex Healthcare Inc
전화
61 409 840 786
주소
401 DOCKLANDS DRIVE, DOCKLANDS, VICTORIA
IXHL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IXHL
Incannex Healthcare Inc
|
1.82 | 32.82M | 0 | -21.91M | 0 | -0.1837 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Incannex Healthcare Inc 주식(IXHL)의 최신 뉴스
Incannex Healthcare Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Incannex Healthcare (NASDAQ:IXHL) Shares Up 5.5% – Still a Buy? - Defense World
Incannex Healthcare (NASDAQ:IXHL) Trading Up 5.5%What's Next? - MarketBeat
Incannex Healthcare Inc (IXHL) Quarterly 10-Q Report - Quartzy
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Incannex Secures $59M Financing, Reports Q1 Results Amid Clinical Trial Progress | IXHL Stock News - StockTitan
Incannex Healthcare names Lou Barbato as chief medical officer - MSN
Incannex appoints new chief medical officer - Investing.com India
Incannex appoints new chief medical officer By Investing.com - Investing.com South Africa
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer - GlobeNewswire
Incannex Healthcare Appoints Dr. Barbato as CMO - TipRanks
Incannex Healthcare Leads The Charge On US Penny Stocks With 2 Other Notable Picks - Simply Wall St
Incannex Healthcare secures $3.3 million through debt financing By Investing.com - Investing.com Australia
Incannex Healthcare secures $3.3 million through debt financing - Investing.com
Incannex Healthcare secures A$6.9 million funding By Investing.com - Investing.com Australia
Incannex Healthcare secures A$6.9 million funding - Investing.com
Incannex Provides Business Updates and Progress on OSA Drug Candidate in Phase 2/3 Trials - Sleep Review
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) - Invezz
R&D tax breaks buoy Incannex as losses narrow - Green Market Report
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Significant Growth in Short Interest - Defense World
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates - The Manila Times
Incannex Healthcare Inc. (NASDAQ:IXHL) Short Interest Update - MarketBeat
Incannex Secures Up to $60M in Financing to Support Clinical Trials - Sleep Review
Incannex secures financing deal valued at US$60 million - Mugglehead
Incannex $60 Million Deal With Arena For Late-Stage Drug TrialsIncannex Healthcare (NASDAQ:IXHL) - Benzinga
Incannex Healthcare secures $60 million funding via equity and debt - Investing.com
Incannex Healthcare secures $60 million funding via equity and debt By Investing.com - Investing.com UK
Incannex Healthcare lands $60 million financing deal - Green Market Report
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors - GlobeNewswire
Incannex secures $60 million in funding for clinical trials - Investing.com
Incannex Healthcare Inc. (NASDAQ:IXHL) Sees Large Growth in Short Interest - MarketBeat
Thinking about buying stock in Altimmune, UiPath, Incannex Healt - GuruFocus.com
Virtu Financial LLC Buys New Shares in Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
4 Psychedelic Stocks to Consider as Clinical Trials Heat up - Investing.com
FDA Review of PsiGAD2 IND complete; clinical trial for - GlobeNewswire
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety - Benzinga
Incannex Healthcare gets FDA nod for Phase 2 trial - Green Market Report
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed - StockTitan
Tidal Investments LLC Buys New Stake in Incannex Healthcare Inc. (NASDAQ:IXHL) - MarketBeat
Tidal Investments LLC Acquires Shares of 423,410 Incannex Healthcare Inc. (NASDAQ:IXHL) - Defense World
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X - GlobeNewswire
Incannex Healthcare Inc (IXHL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
1.03%
자본화:
|
볼륨(24시간):